This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Can AI-Driven Efficiency and Specialty Demand Boost MCK's Q1 Results?
by Zacks Equity Research
McKesson heads into Q1 with AI-driven efficiency, specialty momentum and oncology growth in focus as pricing dynamics may temper revenues.
MCKNegative Net Change CAHNegative Net Change CORNegative Net Change
medical medical-devices
BrightSpring Q2 Earnings Beat on Specialty Growth, '26 View Raised
by Zacks Equity Research
BTSG's Q2 earnings and revenues beat estimates as pharmacy and provider growth drive margin gains and a higher 2026 outlook.
BTSGPositive Net Change CAHNegative Net Change MCKNegative Net Change PAHCNegative Net Change
earnings medical medical-devices
Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?
by Zacks Equity Research
DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.
DVAPositive Net Change ADUSPositive Net Change AVAHPositive Net Change LFSTPositive Net Change
earnings medical medical-devices
Solventum to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.
SOLVPositive Net Change APositive Net Change CAHNegative Net Change CORNegative Net Change
medical medical-devices
Thermo Fisher Raises 2026 Outlook After Strong Second-Quarter Results
by Moumi Mondal
TMO lifted its 2026 outlook after Q2 topped estimates, driven by stronger demand, acquisitions and margin gains. Can the momentum continue?
TMOPositive Net Change DHRPositive Net Change APositive Net Change
earnings-performance medical medical-devices
CVS Health's Q2 Earnings on Deck: How Should You Play the Stock?
by Moumi Mondal
CVS heads into Q2 earnings with estimates pointing to revenue and EPS growth as Aetna initiatives and key business segments support results.
CVSNegative Net Change UNHPositive Net Change ELVPositive Net Change
earnings-preview medical medical-devices
DexCom Stock Up on Q2 Earnings & Revenue Beat, Margins Rise
by Zacks Equity Research
DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.
DXCMPositive Net Change CAHNegative Net Change MCKNegative Net Change PAHCNegative Net Change
earnings medical medical-devices
GMED's Q2 Earnings on Deck: Will Enabling Technologies Lead Results?
by Zacks Equity Research
Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.
GMEDPositive Net Change CAHNegative Net Change CVSNegative Net Change CORNegative Net Change
medical medical-devices
MMSI Q2 Earnings & Revenues Beat Estimates, '26 Guidance Raised
by Zacks Equity Research
Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.
MMSIPositive Net Change CAHNegative Net Change MCKNegative Net Change WSTPositive Net Change
earnings medical medical-devices
OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth
by Zacks Equity Research
Omnicell highlights Titan XT and OmniSphere momentum, and raises profit outlook, while customer approval timing weighs on product bookings.
OMCLPositive Net Change
earnings medical-devices